- 全部删除
您的购物车当前为空
Flonoltinib (JAK2/FLT3-IN-1)是一种具有口服活性和高效性的 JAK2/FLT3 抑制剂,抑制 JAK2,FLT3,JAK1 和 JAK3。Flonoltinib 具有抗癌活性,可用于研究骨髓增生性肿瘤 。

Flonoltinib (JAK2/FLT3-IN-1)是一种具有口服活性和高效性的 JAK2/FLT3 抑制剂,抑制 JAK2,FLT3,JAK1 和 JAK3。Flonoltinib 具有抗癌活性,可用于研究骨髓增生性肿瘤 。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 345 | In stock | |
| 5 mg | ¥ 768 | In stock | |
| 10 mg | ¥ 1,220 | In stock | |
| 25 mg | ¥ 1,960 | In stock | |
| 50 mg | ¥ 3,230 | In stock | |
| 100 mg | ¥ 4,630 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 838 | In stock |
Flonoltinib 相关产品
| 产品描述 | Flonoltinib (JAK2/FLT3-IN-1) is an orally active and potent JAK2/FLT3 inhibitor, inhibiting JAK2, FLT3, JAK1, and JAK3. Flonoltinib has anti-cancer activity and can be used for studying myeloproliferative neoplasms. |
| 靶点活性 | FLT3:4 nM, JAK3:39 nM, JAK2:0.7 nM, JAK1:26 nM |
| 体外活性 | Flonoltinib (0.005 - 0.1 μM,2小时)对诱导 MV4-11 细胞凋亡具有剂量依赖性。 |
| 体内活性 | Flonoltinib 在 mv4 -11 小鼠模型中表现出显著的抗肿瘤作用,肿瘤生长抑制率(TGI)分别为 58% 和 93%。[1] |
| 别名 | JAK2/FLT3-IN-1 |
| 分子量 | 467.58 |
| 分子式 | C25H34FN7O |
| CAS No. | 2387765-27-5 |
| Smiles | FC1=CC(=CC=C1N2CCC(N(C)CCO)CC2)NC=3N=CC(=C(N3)C=4C=NN(C4)C(C)C)C |
| 密度 | 1.26 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| 溶解度信息 | DMSO: 20 mg/mL (42.77 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
评论内容